Treatment guidelines for migraine rank the evidence supporting triptan therapy in the highest tier – that is, established as effective for acute migraine treatment based on available evidence.[Marmura et al., 2015; Worthington et al., 2013] Individual triptan therapies have been tested in rigorous clinical development programmes, with efficacy and safety assayed against placebo or comparators.[Marmura et al., 2015]
References:
Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache 2015; 55 (1): 3–20.
Worthington I, Pringsheim T, Gawel MJ, et al. Canadian Headache Society Guideline: acute drug therapy for migraine headache. Can J Neurol Sci 2013; 40 (5 Suppl 3): S1–S80.
Other references used on slide:
Antonaci F, Ghiotto N, Wu S, et al. Recent advances in migraine therapy. Springerplus 2016; 5: 637.
Eigenbrodt, AK, Ashina H, Khan S, Diener HC, Mitsikostas D, Sinclair AJ, … & Ashina M. Diagnosis and management of migraine in ten steps. Nat Rev Neurol 2021, 17(8): 501-514.
Tepper SJ, Rapoport AM, Sheftell FD. Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch Neurol 2002; 59 (7): 1084–1088.
